India Therapeutics Market Size & Growth Rate
According to 6Wresearch internal database and industry insights, the India Therapeutics Market was valued at USD 631.0 million in 2025 and is projected to reach USD 858.70 million by 2032, growing at a CAGR of approximately 4.5% during 2026–2032.
India Therapeutics Market Highlights
| Report Metric | Details |
| Report Name | India Therapeutics Market |
| Market Size 2025 | USD 631.0 million |
| Market Size 2032 | USD 858.70 million |
| Absolute Growth 2025–2032 | USD 227.70 million |
| CAGR 2026–2032 | 4.5% |
| Peak Annual Growth | 6.4% in 2027 |
| Forecast Period | 2026–2032 |
| Historical Data | 2022–2025 |
| Base Year | 2025 |
| Leading Product Type, 2025 | Biologics (42% share) |
| Leading Disease Category, 2025 | Chronic Illnesses (40% share) |
| Leading Drug Format, 2025 | Injectables (43% share) |
| Leading End User, 2025 | Hospitals (43% share) |
| Fastest-Growing Product Type | Small Molecule Drugs (6.7% CAGR) |
| Fastest-Growing Disease Category | Acute Diseases (5.7% CAGR) |
| Fastest-Growing Drug Format | Oral Tablets (6.6% CAGR) |
| Fastest-Growing End User | Clinics (7.2% CAGR) |
| Growing Sector | Hospitals |
| Key End Users | Hospitals, Clinics, Specialty Hospitals, Research Institutions |
India Therapeutics Market Year-wise Growth Rate and Key Drivers (2022–2032)
This graph illustrates the annual growth rates of the market from 2022 to 2032, highlighting a steady upward trajectory and projected market expansion over the forecast period.
Year by year, the estimates below pair each growth rate with the development that shaped it.
| Year | Estimated Annual Growth (%) | Market Rationale |
| 2022 | 4.8 | The market experienced steady growth due to the National Health Mission improving healthcare access across urban areas. |
| 2023 | 4.4 | Demand growth slowed as hospitals adjusted to new therapeutic protocols and patient flows. |
| 2024 | 5.2 | The introduction of new biologics spurred faster growth as hospitals expanded treatment options. |
| 2025 | 6.0 | A surge in chronic illness cases led to heightened therapeutic demand, marking a peak in growth. |
| 2026 | 1.9 | Growth is projected to slow as regulatory changes impact product approval timelines. |
| 2027 | 6.4 | The introduction of new therapies is expected to revitalise the market, driving demand higher again. |
| 2028 | 5.4 | A slight slowdown is anticipated as hospitals focus on cost management and efficiency measures. |
| 2029 | 4.3 | Demand is expected to continue slowing as healthcare providers adjust to changing patient demographics. |
| 2030 | 2.5 | The market is projected to experience further slowdown due to budget constraints in healthcare spending. |
| 2031 | 5.2 | Growth is anticipated to accelerate again as new treatment guidelines are adopted by healthcare facilities. |
| 2032 | 5.9 | The market is projected to grow as investments in healthcare infrastructure increase. |
Note: Market size estimations and growth projections presented in this report are based on 6Wresearch's proprietary forecasting methodology, utilizing the latest available industry data, government publications, and primary research inputs.
India Therapeutics Market Synopsis
Therapeutics in India encompasses a range of medical treatments aimed at alleviating disease symptoms and improving quality of life. This includes biologics, small molecule drugs, RNA therapies, and cell-based therapies. The India Therapeutics Market is expanding due to the high prevalence of chronic illnesses and increasing healthcare investments. Approximately 70% of the population is affected by chronic illnesses, driving demand for effective treatments. The National Health Mission aims to improve healthcare access, further stimulating market growth.
Market Dynamics Impact Analysis (2026–2032)
| Factor | Type | Impact | Primary Segment Affected |
| Increasing prevalence of chronic illnesses drives demand for effective therapeutics. | Driver | High | Chronic Illnesses |
| The expansion of healthcare facilities increases access to therapeutic options. | Driver | High | Hospitals |
| Emerging demand for biologics presents opportunities for new product development. | Opportunity | High | Biologics |
| The rise of specialty hospitals focusing on oncology creates new market segments. | Opportunity | Medium | Specialty Hospitals |
| Regulatory hurdles can delay product approvals, impacting market entry. | Restraint | High | Biologics |
| High costs associated with advanced therapies limit accessibility for some patients. | Restraint | Medium | Biologics |
| Supply chain disruptions can affect the availability of critical therapeutics. | Challenge | High | Biologics |
| Technological advancements require constant adaptation from producers, complicating operations. | Challenge | Medium | Biologics |
Evaluation of Drivers in India Therapeutics Market (2026–2032)
The factors lifting demand, and the evidence behind each, are summarised below.
| Drivers | Primary Segment Affected | Why It Matters (Evidence) |
| Rising prevalence of chronic illnesses increases demand for therapeutics. | Chronic Illnesses | Approximately 70% of the Indian population is affected by chronic illnesses, increasing therapeutic needs. |
| Expansion of healthcare facilities improves access to therapeutic treatments. | Hospitals | India has over 1,500 hospitals providing therapeutic services, which enhances patient access. |
| Growing investment in research and development fuels innovation in therapeutics. | Biologics | India produces over 20% of the world's generic drugs, including therapeutics, which drives innovation. |
| Increased patient awareness about treatment options boosts demand for therapeutics. | Biologics | The National Health Mission aims to improve healthcare access, leading to informed patient choices. |
| Technological advancements in drug development improve therapeutic options. | Small Molecule Drugs | New drug formats and delivery systems are being developed to improve patient outcomes. |
Expansion of the Therapeutics market in India is backed by rising prevalence of chronic illnesses, increasing healthcare facility access, and growing investments in research and development. Chronic illnesses affect approximately 70% of the population, creating a significant demand for effective treatments. The presence of over 1,500 hospitals providing therapeutic services enhances patient access to necessary care. India produces over 20% of the world's generic drugs, which supports innovation in therapeutics. The National Health Mission's efforts to improve healthcare access further stimulate market growth, encouraging informed patient choices and expanding treatment options.
Evaluation of Restraints in India Therapeutics Market
The following restraints limit how fast demand can grow.
| Market Restraint | Primary Segment Affected | Why It Matters (Evidence) |
| Regulatory hurdles delay product approvals, affecting market entry. | Biologics | The Drug Controller General of India oversees therapeutic product approvals, which can be lengthy. |
| High costs of advanced therapies limit accessibility for some patients. | Biologics | The cost of biologics can be prohibitive, affecting patient access to necessary treatments. |
| Supply chain disruptions can impact the availability of critical therapeutics. | Biologics | Recent global events have highlighted vulnerabilities in the supply chain for pharmaceuticals. |
| Limited awareness of new therapies among patients can hinder adoption. | Biologics | Patient education initiatives are still developing, affecting treatment uptake. |
| Intense competition among manufacturers can lead to pricing pressures. | Biologics | The market is crowded with numerous players, impacting profit margins. |
India Therapeutics Market Challenges
Buyers and suppliers in the India therapeutics market confront rising costs as chronic illnesses affect about 70% of the population, putting pressure on healthcare budgets. The adoption of new technologies is slow, with over 300 research institutions generating innovations that have not yet reached widespread use, delaying patient access to effective treatments. Regulatory challenges remain, as the Drug Controller General of India may take months to approve new therapeutics, resulting in missed market opportunities for suppliers. Supply chain issues are apparent, with over 60% of therapeutic demand concentrated in urban areas, complicating distribution to rural regions and increasing operational costs.
Trends in the India Therapeutics Market
The trends below show where the India Therapeutics Market is heading.
- Shift from Traditional to Biologics: The Indian therapeutics market is transitioning from traditional small molecule drugs to biologics, which are becoming more popular due to their targeted approach. By 2025, the biologics segment is expected to secure a substantial market share, improving treatment effectiveness.
- Increase in Specialty Hospitals: Specialty hospitals concentrating on oncology and chronic diseases are rapidly emerging, indicating a shift in treatment paradigms. By 2025, these facilities are projected to significantly increase their share of therapeutic services, addressing specific patient requirements.
- Growing Use of Injectables: Injectables are increasingly favoured for their immediate therapeutic effects, representing nearly 40% of the market. This trend is driven by the necessity for rapid treatment in critical care environments, especially within hospitals.
- Rise of Oral Tablets: Oral tablets are becoming the preferred choice for chronic disease management, reflecting a move towards more convenient treatment options. This format is anticipated to grow at a CAGR of 6.6% between 2026 and 2032, indicating strong demand.
Investment Opportunities in the India Therapeutics Market
Some of the investment opportunities in the India Therapeutics Market are mentioned below.
- Increasing Demand for Biologics: The biologics segment is set for growth due to rising chronic illness cases, with the market projected to reach significant levels by 2025. Investing in biologics production can benefit manufacturers targeting hospitals and specialty clinics.
- Expansion of Specialty Hospitals: The rapid emergence of specialty hospitals focusing on oncology presents a unique opportunity for suppliers to provide targeted therapeutics. With a growing patient base, partnerships with these facilities can enhance market presence.
- Focus on Advanced Therapeutics: The increasing focus on advanced therapies, particularly for autoimmune diseases, creates opportunities for innovative product development. Collaborating with research institutions can facilitate entry into this expanding market segment.
- Growth in Outpatient Services: The rise of outpatient therapeutic services, particularly in clinics, is driving demand for oral tablets and injectables. Suppliers can tap into this market by providing tailored solutions to outpatient facilities.
Government Initiatives in the India Therapeutics Market
The Drugs and Cosmetics Act regulates therapeutic products in India, ensuring safety and efficacy. The National Health Policy 2017 aims to improve healthcare access and quality, targeting a 2.5% GDP expenditure by 2025, which will impact therapeutic availability. Additionally, the National Biotechnology Development Strategy promotes biologics development, encouraging innovation in therapeutic solutions.
The BioNEST program, launched by the Biotechnology Industry Research Assistance Council (BIRAC) in 2021, supports biotech startups focusing on therapeutics with a budget of INR 500 crores. The Production Linked Incentive (PLI) Scheme, initiated by the Department of Pharmaceuticals in 2020, aims to boost domestic manufacturing of pharmaceuticals, including therapeutics, with a budget of INR 15,000 crores. These initiatives aim to improve production capabilities and ensure a steady supply of therapeutics.
Future Insight of the India Therapeutics Market
The India therapeutics market will experience substantial changes by 2032, with the National Health Mission set to enhance healthcare access for millions. The biologics segment is expected to capture a larger market share, driven by the National Biotechnology Development Strategy, which promotes research and development in this area. Clinical trials for new therapeutics are anticipated to increase, providing patients with more diverse treatment options. The Ayushman Bharat scheme aims to deliver affordable healthcare to 500 million people, broadening the reach of essential therapeutic services.
Market Segmentation Analysis
The report offers a comprehensive study of the following market segments and their leading categories in the market.
By Product Type – Biologics Dominated, Small Molecule Drugs Expected to Grow Fastest
According to Vasudha, AM at 6Wresearch, with a 42% revenue share in 2025, Biologics was the largest product type category. Biologics hold the largest market share in India as they are crucial for treating various diseases, supported by over 300 research institutions focusing on therapeutics. Their significance is highlighted by the increasing prevalence of chronic illnesses, impacting around 70% of the population. Small Molecule Drugs are set to record the highest CAGR in this split, 6.7% over 2026–2032. The small molecule drugs segment is experiencing rapid growth, primarily due to their widespread prescription for numerous conditions, making them essential in outpatient care. This surge is further propelled by the rising incidence of chronic diseases that require continuous management. Suppliers should prioritise expanding their small molecule drug offerings to meet the growing outpatient demand.
By Disease Category – Chronic Illnesses Dominated, Acute Diseases Expected to Grow Fastest
Chronic Illnesses took a 40% share of disease category in 2025, more than any other category. Chronic illnesses hold the largest market share as they are a primary focus for therapeutic treatments, impacting approximately 70% of the Indian population. Initiatives like the National Health Mission aim to improve management and access to therapies for these conditions. Acute Diseases are projected to grow fastest, at a CAGR of 5.7% during 2026–2032. Acute diseases are experiencing the fastest growth rate, driven by the urgent need for effective therapeutic interventions in emergency situations. This is evidenced by the rising number of patients requiring immediate care in hospitals and clinics. Buyers should prioritise therapies that address acute diseases to ensure timely and effective patient management.
By Drug Format – Injectables Dominated, Oral Tablets Expected to Grow Fastest
Injectables accounted for a 43% market share by drug format in 2025. Injectables command the largest market share due to their ability to provide immediate therapeutic effects, making them essential in hospital settings. Nearly 40% of the therapeutic market is attributed to injectables, reflecting their critical role in treatment protocols. Over 2026–2032, Oral Tablets are expected to post the fastest growth, at a CAGR of 6.6%. Oral tablets are growing rapidly as the most common format for chronic disease management, driven by their convenience and ease of administration. This format's popularity is underscored by the increasing number of patients requiring ongoing treatment for chronic conditions. Suppliers should expand their oral tablet offerings to capture the growing demand for chronic disease management.
By End User – Hospitals Dominated, Clinics Expected to Grow Fastest
In 2025, Hospitals led the end user split with a 43% share. Hospitals are the primary end-users of therapeutics, capturing a substantial market share due to their extensive treatment capabilities. With over 1,500 hospitals providing therapeutic services, they play a vital role in patient care across India. The quickest growth will come from Clinics, forecast to expand at a CAGR of 7.2% between 2026 and 2032. Clinics are seeing the fastest growth in demand for outpatient therapeutic services, indicating a shift towards more decentralised healthcare delivery. This trend is driven by an increasing number of patients seeking prompt treatment without hospitalisation. Suppliers should create targeted strategies to address the rising demand for therapeutics in clinic settings.
Key Attractiveness of the Report
- 10 Years of Market Numbers
- Historical Data Starting from 2022 to 2025
- Base Year 2025
- Forecast Data until 2032
- Key Performance Indicators Impacting the Market
- Major Upcoming Developments and Projects
Key Highlights of the Report:
- India Therapeutics Market Outlook
- Market Size of India Therapeutics Market, 2025
- Forecast of India Therapeutics Market, 2032
- Historical Data and Forecast of India Therapeutics Revenues & Volume for the Period 2022 - 2032F
- India Therapeutics Market Trend Evolution
- India Therapeutics Market Drivers and Challenges
- India Therapeutics Price Trends
- India Therapeutics Porter's Five Forces
- India Therapeutics Industry Life Cycle
- Historical Data and Forecast of India Therapeutics Market Revenues & Volume By Product Type for the Period 2022 - 2032F
- Historical Data and Forecast of India Therapeutics Market Revenues & Volume By Biologics for the Period 2022 - 2032F
- Historical Data and Forecast of India Therapeutics Market Revenues & Volume By Small Molecule Drugs for the Period 2022 - 2032F
- Historical Data and Forecast of India Therapeutics Market Revenues & Volume By RNA Therapies for the Period 2022 - 2032F
- Historical Data and Forecast of India Therapeutics Market Revenues & Volume By Cell-Based Therapies for the Period 2022 - 2032F
- Historical Data and Forecast of India Therapeutics Market Revenues & Volume By Disease Category for the Period 2022 - 2032F
- Historical Data and Forecast of India Therapeutics Market Revenues & Volume By Chronic Illnesses for the Period 2022 - 2032F
- Historical Data and Forecast of India Therapeutics Market Revenues & Volume By Acute Diseases for the Period 2022 - 2032F
- Historical Data and Forecast of India Therapeutics Market Revenues & Volume By Genetic Disorders for the Period 2022 - 2032F
- Historical Data and Forecast of India Therapeutics Market Revenues & Volume By Autoimmune/Oncology for the Period 2022 - 2032F
- Historical Data and Forecast of India Therapeutics Market Revenues & Volume By Drug Format for the Period 2022 - 2032F
- Historical Data and Forecast of India Therapeutics Market Revenues & Volume By Injectables for the Period 2022 - 2032F
- Historical Data and Forecast of India Therapeutics Market Revenues & Volume By Oral Tablets for the Period 2022 - 2032F
- Historical Data and Forecast of India Therapeutics Market Revenues & Volume By IV/Injectable for the Period 2022 - 2032F
- Historical Data and Forecast of India Therapeutics Market Revenues & Volume By Infusions for the Period 2022 - 2032F
- Historical Data and Forecast of India Therapeutics Market Revenues & Volume By End User for the Period 2022 - 2032F
- Historical Data and Forecast of India Therapeutics Market Revenues & Volume By Hospitals for the Period 2022 - 2032F
- Historical Data and Forecast of India Therapeutics Market Revenues & Volume By Clinics for the Period 2022 - 2032F
- Historical Data and Forecast of India Therapeutics Market Revenues & Volume By Research Institutions for the Period 2022 - 2032F
- Historical Data and Forecast of India Therapeutics Market Revenues & Volume By Specialty Hospitals for the Period 2022 - 2032F
- India Therapeutics Import Export Trade Statistics
- Market Opportunity Assessment By Product Type
- Market Opportunity Assessment By Disease Category
- Market Opportunity Assessment By Drug Format
- Market Opportunity Assessment By End User
- India Therapeutics Top Companies Market Share
- India Therapeutics Competitive Benchmarking By Technical and Operational Parameters
- India Therapeutics Company Profiles
- India Therapeutics Key Strategic Recommendations
Market Covered
The report offers an extensive study of the following market segments.
By Product Type
- Biologics
- Small Molecule Drugs
- RNA Therapies
- Cell-Based Therapies
By Disease Category
- Chronic Illnesses
- Acute Diseases
- Genetic Disorders
- Autoimmune/Oncology
By Drug Format
- Injectables
- Oral Tablets
- IV/Injectable
- Infusions
By End User
- Hospitals
- Clinics
- Research Institutions
- Specialty Hospitals
